{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T13:11:24Z","timestamp":1778937084441,"version":"3.51.4"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T00:00:00Z","timestamp":1711065600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA240301"],"award-info":[{"award-number":["CA240301"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA240423"],"award-info":[{"award-number":["R01 CA240423"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["572533"],"award-info":[{"award-number":["572533"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Pathogenesis and Therapy"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.cpt.2024.03.003","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T13:34:33Z","timestamp":1711460073000},"page":"68-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Loss of phosphatase and tensin homolog (PTEN) increases Lysyl oxidase-like 2 (LOXL2) expression enhancing the growth of fallopian tube epithelial cells as three-dimensional spheroids"],"prefix":"10.1016","volume":"3","author":[{"given":"Angela","family":"Russo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1117-3137","authenticated-orcid":false,"given":"Junlone","family":"Moy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5744-9584","authenticated-orcid":false,"given":"Manead","family":"Khin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy R.","family":"Dorsey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Lopez Carrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7271-6847","authenticated-orcid":false,"given":"Joanna E.","family":"Burdette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpt.2024.03.003_bib1","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ajpath.2020.09.006","article-title":"The origin of ovarian cancer species and precancerous landscape","volume":"191","author":"Shih","year":"2021","journal-title":"Am J Pathol"},{"key":"10.1016\/j.cpt.2024.03.003_bib2","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1038\/oncsis.2016.8","article-title":"Gain of function of mutant p53: R282W on the peak?","volume":"5","author":"Zhang","year":"2016","journal-title":"Oncogenesis"},{"key":"10.1016\/j.cpt.2024.03.003_bib3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000446361","article-title":"Mutant p53 gain of function and chemoresistance: the role of mutant p53 in response to clinical chemotherapy","volume":"62","author":"He","year":"2017","journal-title":"Chemotherapy"},{"key":"10.1016\/j.cpt.2024.03.003_bib4","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.ccr.2013.10.013","article-title":"Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models","volume":"24","author":"Perets","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cpt.2024.03.003_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0065067","article-title":"Conditional inactivation of p53 in mouse ovarian surface epithelium does not alter MIS driven Smad2-dominant negative epithelium-lined inclusion cysts or teratomas","volume":"8","author":"Quartuccio","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cpt.2024.03.003_bib6","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/path.4417","article-title":"The PAX2-null immunophenotype defines multiple lineages with common expression signatures in benign and neoplastic oviductal epithelium","volume":"234","author":"Ning","year":"2014","journal-title":"J Pathol"},{"key":"10.1016\/j.cpt.2024.03.003_bib7","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1177\/1947601911407325","article-title":"PTEN tumor suppressor network in PI3K-Akt pathway control","volume":"1","author":"Georgescu","year":"2010","journal-title":"Genes Cancer"},{"key":"10.1016\/j.cpt.2024.03.003_bib8","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1002\/ijc.29528","article-title":"Mutant p53 expression in fallopian tube epithelium drives cell migration","volume":"137","author":"Quartuccio","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cpt.2024.03.003_bib9","doi-asserted-by":"crossref","first-page":"20500","DOI":"10.18632\/oncotarget.3985","article-title":"Tumorigenesis and peritoneal colonization from fallopian tube epithelium","volume":"6","author":"Eddie","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.cpt.2024.03.003_bib10","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1038\/s41388-017-0097-8","article-title":"PTEN loss in the fallopian tube induces hyperplasia and ovarian tumor formation","volume":"37","author":"Russo","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.cpt.2024.03.003_bib11","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1055\/s-0043-118907","article-title":"PI3K\/AKT\/mTOR pathway in ovarian cancer treatment: are we on the right track?","volume":"77","author":"Gasparri","year":"2017","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"10.1016\/j.cpt.2024.03.003_bib12","doi-asserted-by":"crossref","first-page":"884","DOI":"10.3390\/cancers11060884","article-title":"Loss of PTEN in fallopian tube epithelium results in multicellular tumor spheroid formation and metastasis to the ovary","volume":"11","author":"Dean","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cpt.2024.03.003_bib13","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1038\/onc.2016.455","article-title":"PAX2 function, regulation and targeting in fallopian tube-derived high-grade serous ovarian cancer","volume":"36","author":"Modi","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.cpt.2024.03.003_bib14","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41419-021-03663-2","article-title":"Silencing PTEN in the fallopian tube promotes enrichment of cancer stem cell-like function through loss of PAX2","volume":"12","author":"Russo","year":"2021","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.cpt.2024.03.003_bib15","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.neo.2018.10.010","article-title":"Stromal PTEN regulates extracellular matrix organization in the mammary gland","volume":"21","author":"Jones","year":"2019","journal-title":"Neoplasia"},{"key":"10.1016\/j.cpt.2024.03.003_bib16","doi-asserted-by":"crossref","first-page":"188435","DOI":"10.1016\/j.bbcan.2020.188435","article-title":"LOXL2 in cancer: regulation, downstream effectors and novel roles","volume":"1874","author":"Wen","year":"2020","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.cpt.2024.03.003_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.23538","article-title":"The prognostic value of the lysyl oxidase family in ovarian cancer","volume":"34","author":"Ye","year":"2020","journal-title":"J Clin Lab Anal"},{"key":"10.1016\/j.cpt.2024.03.003_bib18","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.canlet.2018.07.003","article-title":"Prolactin signaling drives tumorigenesis in human high grade serous ovarian cancer cells and in a spontaneous fallopian tube derived model","volume":"433","author":"Karthikeyan","year":"2018","journal-title":"Cancer Lett"},{"key":"10.1016\/j.cpt.2024.03.003_bib19","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3389\/fonc.2015.00245","article-title":"The extracellular matrix in epithelial ovarian cancer - a piece of a puzzle","volume":"5","author":"Cho","year":"2015","journal-title":"Front Oncol"},{"key":"10.1016\/j.cpt.2024.03.003_bib20","doi-asserted-by":"crossref","first-page":"6417","DOI":"10.1158\/1078-0432.CCR-19-0187","article-title":"Anticancer immunotherapy by MFAP5 blockade inhibits fibrosis and enhances chemosensitivity in ovarian and pancreatic cancer","volume":"25","author":"Yeung","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cpt.2024.03.003_bib21","doi-asserted-by":"crossref","first-page":"11745","DOI":"10.3390\/ijms241411745","article-title":"Multiple roles of LOXL2 in the progression of hepatocellular carcinoma and its potential for therapeutic targeting","volume":"24","author":"Radic","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cpt.2024.03.003_bib22","first-page":"38","article-title":"A serological marker of the N-terminal neoepitope generated during LOXL2 maturation is elevated in patients with cancer or idiopathic pulmonary fibrosis","volume":"17","author":"Leeming","year":"2019","journal-title":"Biochem Biophys Rep"},{"key":"10.1016\/j.cpt.2024.03.003_bib23","doi-asserted-by":"crossref","first-page":"26066","DOI":"10.18632\/oncotarget.15257","article-title":"Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer","volume":"8","author":"Chang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.cpt.2024.03.003_bib24","first-page":"573","article-title":"Targeting the PI3K\/AKT\/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer","volume":"4","author":"Rinne","year":"2021","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.cpt.2024.03.003_bib25","doi-asserted-by":"crossref","first-page":"949","DOI":"10.3390\/cancers11070949","article-title":"PI3K-AKT-mTOR and NFkappaB pathways in ovarian cancer: implications for targeted therapeutics","volume":"11","author":"Ghoneum","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cpt.2024.03.003_bib26","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.semcancer.2019.05.012","article-title":"Role of the PI3K\/AKT\/mTOR signaling pathway in ovarian cancer: biological and therapeutic significance","volume":"59","author":"Ediriweera","year":"2019","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.cpt.2024.03.003_bib27","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.3892\/ijmm.2015.2337","article-title":"The function and mechanisms of action of LOXL2 in cancer (Review)","volume":"36","author":"Wu","year":"2015","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.cpt.2024.03.003_bib28","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","article-title":"Ovarian cancer development and metastasis","volume":"177","author":"Lengyel","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.cpt.2024.03.003_bib29","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/modpathol.2016.238","article-title":"Serous tubal intraepithelial neoplasia: the concept and its application","volume":"30","author":"Meserve","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1016\/j.cpt.2024.03.003_bib30","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1007\/s12094-023-03133-5","article-title":"Phosphorylation of AKT by lysyl oxidase-like 2 activates the PI3K\/AKT signaling pathway to promote proliferation, invasion and metastasis in esophageal squamous carcinoma","volume":"25","author":"Fan","year":"2023","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.cpt.2024.03.003_bib31","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1093\/carcin\/bgt241","article-title":"Lysyl oxidase-like-2 promotes tumour angiogenesis and is a potential therapeutic target in angiogenic tumours","volume":"34","author":"Zaffryar-Eilot","year":"2013","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.cpt.2024.03.003_bib32","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1002\/ptr.8066","article-title":"Luteolin, a flavone ingredient: anticancer mechanisms, combined medication strategy, pharmacokinetics, clinical trials, and pharmaceutical researches","volume":"38","author":"Shi","year":"2024","journal-title":"Phytother Res"},{"key":"10.1016\/j.cpt.2024.03.003_bib33","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3390\/antiox10020312","article-title":"LOXL2 inhibitors and breast cancer progression","volume":"10","author":"Ferreira","year":"2021","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.cpt.2024.03.003_bib34","doi-asserted-by":"crossref","first-page":"76881","DOI":"10.18632\/oncotarget.20173","article-title":"PAX2 maintains the differentiation of mouse oviductal epithelium and inhibits the transition to a stem cell-like state","volume":"8","author":"Alwosaibai","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.cpt.2024.03.003_bib35","doi-asserted-by":"crossref","first-page":"71362","DOI":"10.18632\/oncotarget.12109","article-title":"Dormant tumor cells expressing LOXL2 acquire a stem-like phenotype mediating their transition to proliferative growth","volume":"7","author":"Weidenfeld","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.cpt.2024.03.003_bib36","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.2217\/fon.12.105","article-title":"LOXL2 in epithelial cell plasticity and tumor progression","volume":"8","author":"Cano","year":"2012","journal-title":"Future Oncol"}],"container-title":["Cancer Pathogenesis and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949713224000223?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949713224000223?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T12:50:47Z","timestamp":1778935847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949713224000223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2949713224000223"],"URL":"https:\/\/doi.org\/10.1016\/j.cpt.2024.03.003","relation":{},"ISSN":["2949-7132"],"issn-type":[{"value":"2949-7132","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Loss of phosphatase and tensin homolog (PTEN) increases Lysyl oxidase-like 2 (LOXL2) expression enhancing the growth of fallopian tube epithelial cells as three-dimensional spheroids","name":"articletitle","label":"Article Title"},{"value":"Cancer Pathogenesis and Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpt.2024.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of Chinese Medical Association (CMA).","name":"copyright","label":"Copyright"}]}}